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Impact of choice of volumetry software and nodule management guidelines on recall rates in lung 
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Abstract 
Purpose  
Appropriate lung nodule management is essential to minimizing unnecessary patient recall in lung 
cancer screening. Two European guidelines provide differing recommendations in that participants 
with nodules ≥100mm3 or ≥80mm3 respectively should be recalled, at baseline.  Nodule size estimation 
is known to vary between volumetry software packages (VSPs). The aim of this study was to examine 
the impact of choice of VSP on participant recall rates, when applying different European nodule 
management guidelines. An additional aim was to compare recall rates between 7 VSPs and manual 
diameter measurements. 
Methods 
156 small-sized lung nodules (50-150mm3) from the UK Lung Screening trial were measured using 7 
different VSPs (VSP1-7) and also using manual diameter. The type of VSP used in the NELSON study 
(VSP1), on which European nodule management guidelines are based, provided the reference 
standard. Nodule size was compared using Bland Altman, and recall rates by Mcnemar’s test.  
Results  
Compared to the reference standard, a 100mm3 threshold for recall, resulted in no difference in recall 
rates only for VSP 5 & 7. Using an 80mm3 threshold resulted in no difference in recall rates for VSP2 & 
6. Recall rates were significantly higher for VSP 4 regardless of threshold and when using manual 
diameter measurements.  
Conclusions 
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Appropriate nodule size thresholds for recall in screening depend on the type of volumetry software 
used. The results highlight the importance of benchmarking of volumetry packages 
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1. Introduction 
Following the National Lung Screening Trial (NLST) [1] and more recently presented results 
from the NELSON trial[2] showing a mortality reduction from lung cancer screening, many European 
countries are deciding whether to implement lung cancer screening with CT. A critical factor in this 
decision will be cost effectiveness, and central to this is the appropriate minimization of false positives. 
Although various definitions of “false positive” have been used in the CT screening literature, a 
practical definition is any screening result that leads to a participant being recalled for further tests, 
including repeat CT, prior to the next scheduled screening round. This has also been referred to as the 
“recall rate” [3, 4].  
Evidence from a number of studies has shown that the use of nodule volumetry software and 
the use of higher nodule size thresholds for repeat CT compared to that used in early lung cancer 
screening trials can reduce recall rates [5]. Based on this evidence, a recent position paper by 
European lung cancer screening investigators recommended that volumetry should be the preferred 
method of nodule size measurement [6]. It also recommended that only participants with solid 
nodules ≥ 100mm3 in volume at baseline should be recalled for repeat CT, while participants with solid 
nodules < 100 mm3 did not require CT before their next scheduled screening round. This was based on 
data from the NELSON lung cancer screening trial which demonstrated that participants with nodules 
≥100mm3 had a significantly increased risk of developing lung cancer [7]. That evidence was generated 
using one particular nodule volumetry software package. 
It is known from a small number of studies that there is a variation in nodule size estimation 
between different volumetry  software packages (VSPs)[8-10]. Therefore, to account for the fact that 
screening programmes would not necessarily have access to the same volumetry sofware used in the 
NELSON study, the British Thoracic Society (BTS) guidelines chose a more cautious cut-off and 
recommended that patients with nodules on CT <80mm3 (instead of 100mm3) did not require early 
recall [11]. 
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Previous studies have not examined the degree to which the choice of nodule VSP and choice 
of nodule volumetry management guideline in combination, influences recall rates in lung cancer 
screening. Therefore, in this study, we aimed to evaluate the impact on recall rates in a CT screening 
population enriched for small sized nodules, using 7 different commercially available VSPs currently 
in use in radiology departments, (including the type of VSP used in the NELSON lung cancer screening 
trial), applying nodule size thresholds for recall of 80mm3 and 100mm3 respectively.   
Since volumetry is not universally available and because volumetry is not usable on all 
nodules, nodule size may sometimes need to be measured using electronic callipers. In this scenario, 
the European position statement recommends that a threshold of ≥5mm nodule diameter should be 
employed before participants are recalled for repeat CT [6]. Therefore, an additional aim of this study 
was to compare recall rates between 7 VSPs and manual diameter measurements.  
 
2. Methods and materials 
The study had ethics approval from the National Research Ethics Service and patient consent 
was obtained.  
2.1 Patient Cohort 
The study population was chosen from the United Kingdom Lung Cancer Screening (UKLS) 
study baseline nodule database, derived from the 1,994 participants randomised to the CT 
intervention arm of the study [4]. Since the purpose of the current study was to examine the impact 
on recall rates when applying either a 80mm3 or 100mm3 cut-off, a cohort of small sized nodules 
centred around this threshold was deliberately chosen for the study. All solid nodules between 50mm3 
and 150mm3 classified as requiring recall at the time of the UKLS study, by  UKLS thoracic radiologists, 
at consecutive baseline CTs from the UKLS study were identified from the UKLS database (n=173 
nodules in 131 patients).  (Benign nodules including those regarded as calcified or intrapulmonary 
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lymph nodes by UKLS radiologists did not require recall in the UKLS study and therefore are not 
included in the current study). 17 nodules were excluded from the analysis because corruption of CT 
data that occurred during image transfer did not allow for analysis using all volumetry packages, 
leaving 156 nodules in 119 subjects in the final dataset.   
 
2.2 Image Acquisition 
Non-contrast thoracic CT images were obtained craniocaudally in suspended maximal 
inspiration.  Axial images were reconstructed at 1-mm thickness with 0.7 increments using a moderate 
spatial frequency kernel. Further details on the UKLS screening trial CT and reading protocol is 
provided elsewhere [4].  
 
2.3 Image Analysis 
All nodules were independently evaluated by one of six radiologists, (ranging between five 
and fourteen years’ experience), on dedicated workstations containing commercially available 
volumetry applications currently in use in radiology departments. Because the thresholds for nodule 
management in the European position statement [6] and British Thoracic Society Guidelines [11] were 
derived from data from the NELSON trial [12], the type of VSP used in the NELSON trial [Syngo MMWP 
LungCare VB10A] is regarded as the reference standard for this study, and referred to as VSP 1.  
The other VSPs tested were Siemens SyngoVia MM Oncology version VB10B;  FUJI Synapse 3d 
version 4.4EU; GE AW 3.2 LungVCAR; Philips Lung Nodule Application (LNA) Extended Brilliance 
Workspace version 4.5.6.52040; Terarecon Aquarious iNtuitiion 4.4.12; and Vitrea Vital images v.6.2. 
As per precedence from previous studies examining nodule software reliability [8, 10] the results for 
these VSPs are blinded and referred to as VSP 2-7 in the results below.  
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To ensure consistency, each radiologist was provided with the axial slice position and 
segmental anatomical location reference for each nodule, as documented in the UKLS database. The 
volume of each nodule was measured according to the specific VSP’s manufacturer’s instructions. This 
was either initiated by the reader clicking the nodule centre, or drawing a line across the nodule. 
Manual alteration of the segmented region was not permitted.  The reliability of automated 
segmentation was subjectively assessed by each reader based on the criteria described by de Hoop et 
al. [8]. That study considered a nodule to be unreliably segmented when the segmented nodule 
volume boundaries were estimated to exceed approximately 30% of the nodule, judged visually. 
Typically, this would occur when the nodule segmentation included adjacent structures such as a 
pulmonary vessel. Nodules that were not reliably segmented were recorded as such.  
A separate analysis was performed by two further thoracic radiologists (with five and seven 
years’ experience) to manually measure the long axis diameter of the same nodule dataset on axial 
CT. Diameters were measured using electronic callipers to one decimal point on a lung window setting 
(W1500,  L -500). 
 
2.4 Statistical Methods 
Nodule volume and diameter were described by median and range. Nodule size using six semi-
automated volumetry software packages (VSP2-7) was compared to nodule size obtained from the 
reference standard, VSP 1, using Bland Altman statistics to illustrate bias and 95% limits of agreement 
[13]. For the purposes of the study, recall rate was determined on a per nodule basis, i.e. each nodule 
was regarded as a separate case.  The proportion of nodules requiring recall using VSP2-7 or manual 
diameter compared to VSP1 was evaluated using Mcnemar’s test. P values < 0.05 were regarded as 
significant. Only nodules that were judged to be adequately segmented by VSP 1 and the comparative 
measurement method were evaluated for each analysis.  All statistical analyses were performed using 
Medcalc version 7.4 software.  
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3. Results 
3.1 Nodule data  
The median and range nodule size for the 156 nodules acquired from the seven VSPs is 
provided in Table 1. The number and proportion of nodules that could not be segmented reliably per 
VSP is also provided in Table 1.  Table 1 also shows median and range nodule diameter measured by 
the two readers.  The distribution of the nodules was as follows:  right upper lobe 40, right middle 
lobe 16, right lower lobe 30, left upper lobe 17, lingula 7 and left lower lobe 46. 
 Compared to VSP 1; VSP 4 and VSP 5 overestimated nodule volume, whereas VSP 2, 3, 6 and 
7 underestimated nodule volume. Nodule volume comparison between VSP 2-7 with their respective 
95% limits of agreement and VSP 1 are provided in Table 2 and visually represented in Bland Altman 
plots, Figures 1.1 to 1.6. 
 
3.2 Influence of nodule volumetry software packages and manual diameter measurement on recall 
rates, when applying European Nodule Management Recommendations 
When using a 100mm3 threshold, the recall rate in this cohort enriched for small nodules 
ranged from 10.0% for VSP 6 to 94.3% for VSP 4 (Table 3). Three VSPs (VSP 2,3 and 6) had significantly 
lower recall rates compared to VSP 1. VSP 5 and VSP 7 showed no difference in recall rates, whereas 
VSP 4 was associated with significantly higher recall rates. The use of manual diameter measurements 
and a 5mm threshold also led to significantly greater recalls for both Reader 1 and Reader 2 compared 
to VSP 1. 
Using an 80mm3 threshold for VSPs 2-7 resulted in significantly higher recall rates for VSP 3, 
4, 5 and 7 compared to VSP 1 (Table 4).  VSP 2 and VSP 6 no longer demonstrated significantly different 
recall rates compared to VSP 1.  
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4. Discussion  
The results from our study suggest that the most appropriate lung nodule size threshold for 
participant recall at baseline lung cancer screening CT should depend on the type of nodule volumetry 
software used. Our study shows that for two of the tested VSPs (VSP 5 and 7), recall rates matched 
the performance of the type of VSP used in the NELSON trial (VSP 1), indicating that the 100mm3 
threshold for recall recommended in the European Lung Cancer Screening Position Statement is 
appropriate.  
The BTS nodule management guidelines deliberately recommended a lower, more cautious 
threshold of 80mm3 for repeat CT, to take into account possible variability in nodule size estimation 
between VSPs. Our results show that for two other VSPs (VSP 2 and VSP 6), that on average 
underestimated nodules size compared to VSP 1, an 80mm3 cut-off for repeat CT was more 
appropriate than 100mm3. 
We also showed that for one VSP (VSP 4), the degree of size overestimation was substantial, 
such that recall rates exceeded 90% regardless of nodule size threshold. However, this particular VSP 
was an outlier. All of the five remaining VSPs had ≤7% difference in recall rates compared to VSP 1, 
when using either an 80mm3 or 100mm3 threshold.  To put this into context, recall rates were 50.7% 
- 59.4% when using manual diameter measurements, highlighting the limitations of electronic calliper 
measurements to accurately measure nodule size. The greater tendency towards unnecessary follow-
up when using diameter compared to the majority of VSPs is important in the context of lung cancer 
screening implementation methodology, where the burden of false positives is cited as a barrier to 
the policy [14]. 
The degree of variation in nodule volume measurements between VSPs was larger in our study 
than that previously reported by Zhao et al. [10] and de Hoop et al. [8]. This could potentially be 
explained by the fact that we tested a greater number of VSPs than previous studies. Indeed, a 
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strength of our study is that we examined a wide range of VSPs currently in use in radiology 
departments, and which might theoretically be used in lung screening programmes today.  Results 
from the study by de Hoop et al [8] for example, (from 2009),  evaluated volumetry software versions 
no longer typically in use. However, it is acknowledged that there are other VSPs currently in use in 
European radiology departments, outside of those tested in our study. Until formal performance 
benchmarking across all vendors is performed, it could be suggested that future screening 
programmes may wish to choose the more cautious threshold of 80mm3 for recall. This may be 
particularly appropriate if, for cost-effectiveness reasons, countries decide to implement biennial 
screening [6] as participants would only undergo a subsequent CT after two years.  
The main limitation of this study is that our results were benchmarked against the type of VSP 
used in the NELSON study and not based upon a true histopathological proven outcomes; therefore it 
is possible that some nodules labelled as “unnecessary recall” may have turned out to be malignant 
in time. However, we believe that it is appropriate to use VSP 1 as the reference standard, as it has 
previously been demonstrated to be a reliable surrogate of outcome in a study of >9000 nodules from 
the NELSON trial [7], and is the basis upon which European nodule management guidelines have been 
based. Furthermore, our results capture what is important in clinical practice, which is whether a 
nodule is actionable based on current guidelines. Second, we only evaluated one aspect of volumetry, 
and did not examine the reliability of volume doubling time calculation which is another important 
feature when using volumetry. We also did not compare intra-package variability, although this is 
more relevant for the reliability of evaluation of nodule size over time and has also previously been 
shown to be minimal [15]. We also focused on solid nodules and did not evaluate subsolid nodules or 
potentially sinister morphological characteristics that would usually be assessed in a clinical context. 
That said for the smaller sized nodules examined in this study it is likely that such differentiating 
characteristics are less meaningful.  
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In conclusion our study is, to the best of our knowledge, the first to examine the reliability of 
a wide range of commercially available nodule volumetry packages currently in use in radiology 
departments, and the corresponding impact on screening recall rates when applying different 
European lung nodule management recommendations. For screening to be successfully implemented, 
clinicians need to know that the VSP used in their screening programme is comparable to those used 
to set guidelines. Further work is need to collate standardised nodule datasets, such that all VSPs can 
be tested for performance and consistency via formal benchmarking exercises.  
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Tables   
Table 1: Nodule size and segmentation reliability 
 
 
VSP 1 VSP 2 VSP 3 VSP 4 VSP 5 VSP 6 VSP7 
Manual 
Diameter 
Reader 1 
Manual 
Diameter 
Reader 2 
Number 
(%) of 
nodules 
not 
reliably 
segmented 
18 (12) 27 (17) 11 (7) 41(26) 22(14) 33 (21) 37 (24) N/A N/A 
Median 
(Range) 
nodule 
size  
[mm3 for 
VSP1-7, 
mm for 
Readers 1 
& 2] 
70.0 
(50.1-
147.8) 
64.9 
(40.2-
157.0) 
60.0 
(18.0-
163.0) 
178.0 
(68.0-
596.0) 
78.6 
(22.3-
385.9) 
52.3 
(21.2-
334.7) 
68.0 
(26.0-
149.0 
4.9  
(2.5 - 
8.3) 
5.1  
(2.9 - 
8.6) 
 
Nodule size and segmentation reliability of the VSPs 1-7, and for two readers using manual diameter. 
N/A= not applicable. 
 
 
 
Table 2: Comparison of nodule volumes  
 VSP 2 VSP 3 VSP 4 VSP 5 VSP 6 VSP 7 
Mean % 
volume 
measurement 
variability  
-12.3  
(-57.7, 
33.0) 
-17.0  
(-64.3, 
30.3) 
+77.0  
(22.4, 
131.6) 
+10.5  
(-37.7, 
58.7) 
-27.0  
(-94.7, 
40.6) 
-5.1  
(-47.7, 
37.2) 
 
Comparison of nodule volumes of VSP 2-7 compared to VSP 1, expressed as mean % volume 
measurement variability (95% limits of agreement).  A negative volume measurement difference 
denotes an underestimation of nodule volume and a positive difference reflects an overestimation of 
nodule volume compared to the reference reading method VSP 1. 
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Table 3.  Comparison of recall rates using a 100mm3 or 5mm diameter threshold, based on European 
Investigators Position Statement Recommendations   
Comparison 
reading 
method 
No. of 
nodules 
VSP 1 Recall 
Rate (%) 
Comparison 
Recall rate 
(%) 
Difference 
(%) p-value 
VSP 2 116 24.1 12.1 -12.0 0.0013 
VSP 3 130 24.6 17.7 -6.9 0.0225 
VSP 4 106 27.4 94.3 66.9 <0.0001 
VSP 5 123 25.2 30.1 4.9 0.1460 
VSP 6 110 20.0 10.0 -10.0 0.0192 
VSP 7 111 26.1 23.4 -2.7 0.4531 
Manual 
Diameter 
Reader 1 
138 26.1 50.7 24.6 <0.0001 
Manual 
Diameter 
Reader 2 
138 26.1 59.4 33.3 <0.0001 
 
Recall rates comparing 100mm3 threshold for VSPs 2-7 and 5mm threshold for Readers 1 & 2 versus 
100mm3 threshold for VSP 1. A negative difference denotes a lower recall rate using the reading 
method as compared to the reference reading method VSP 1.  
 
 
Table 4.  Comparison of recall rates using a 80mm3 threshold, based on British Thoracic Society 
Recommendations  
 
Comparison 
Reading 
method 
No. of 
nodules 
VSP 1 
Recall Rate 
(%) 
Comparison 
Recall rate 
(%) 
Difference 
(%) 
p-value 
VSP 2 116 24.1 26.7 2.6 0.6291 
VSP 3 130 24.6 31.5 6.9 0.0117 
VSP 4 106 27.4 99.1 71.7 <0.0001 
VSP 5 123 25.2 50.4 25.2 <0.0001 
VSP 6 110 20.0 19.1 -0.9 1.0 
VSP 7 111 26.1 36.0 9.9 0.0074 
 
Recall rates comparing 80mm3 threshold for VSPs 2-7 versus 100mm3 threshold for VSP 1. A 
negative difference denotes a lower recall date using the reading method as compared to the 
reference reading method VSP 1. 
 
 
 
 
 
 
 
